Found 706 clinical trials
Phase 2 Trial of AGEN2034 (anti-PD-1) as a Monotherapy of Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
The research study is being conducted to study the PD-1 antibody, AGEN2034 alone, or in combination with the CTLA-4 antibody, AGEN1884, in women with recurrent cervical cancer. Subjects will be asked to complete the following research procedures: 12 lead electrocardiogram (ECG) and evaluation of heart function (to determine heart health). …
UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
Randomized Study of Cranial Blocks for Postoperative Anesthesia to Reduce Pain and Postoperative Opioid Usage
The research study is being conducted to look at the effectiveness of analgesia (pain medication) by scalp nerve block with various medications that will help doctors to more effectively control pain after surgery and for a longer period of time.
A Clinical Study to Evaluate Ambulatory Counterpulsation for the Treatment of Advanced Heart Failure: A Feasibility Study
The purpose of this study is to: assess if the iVAS can help improve blood circulation, gain a better understanding of how this device could impact your health, determine human interaction with the device, and assess the portability of this device.
UPCC 57418: A Phase III Multicenter Randomized Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
This is a study of the effectiveness and safety of giving the experimental drug, APR-246, together with the drug azacitidine to patients with MDS that has not yet been treated with chemotherapy or hypomethylating agents like azacitidine, compared with just giving azacitidine alone.
Study to determine the safety tolerability pharmacokinetics and pharmacodynamics of DNL201 in subjects with Parkinsons Disease
The purpose of this research is to investigate whether DNL201 (the study drug) is safe and tolerable in Parkinson’s disease patients and to investigate how DNL201 is absorbed, broken down, and eliminated from the body.
A Phase 1 Randomized Placebo-Controlled Blinded Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus Sjogrens Syndrome Systemic Sclerosis Polymyositis and Dermatomyositis
A Phase 1, randomized, blinded,placebo-controlled study to evaluate the safety and tolerability of multiple-ascending SC doses of VIB7734 in selected autoimmune diseases (SLE, CLE, Sjogrens syndrome, systemic sclerosis, polymyositis, dermatomyositis), and efficacy on skin lupus activity. 32 subjects will be enrolled in 3 cohorts. Cohort 1 has been completed. 24 …
Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552) evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F) Injection PET MPI, …
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin Hizentra) in Adults with Dermatomyositis (DM)
This is a phase 3, 56-week, multicenter, randomized, placebo controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). Subjects will be randomized to 1 of 2 treatment sequences: Sequence A: 0.5 g/kg IgPro20 for 24 weeks followed by 0.5 g/kg IgPro20 for 28 weeks or …
Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea on Sympathetic and Vascular Function
The hypoglossal nerve controls tongue movement. The Inspire® sleep implant works by stimulating this nerve. This process is called hypoglossal nerve stimulation, or “HGNS.” In this study, we are interested in seeing how HGNS affects blood pressure and heart-related measures and if it lowers the risk of heart problems in …
